Safety and effectiveness of long-term budesonide treatment in maintaining remission in patients with mild-to-moderate Crohn's disease [2]

Inflammatory Bowel Diseases

Volumn 13, Issue 9, 2007, Pages 1184-1186

  Tursi, Antonio ^a   Giorgetti, Gian Marco ^b   Brandimarte, Giovanni ^c   Elisei, Walter ^c  

^a Lorenzo Bonomo Hospital   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

^c Cristo Re Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; INFLIXIMAB; STEROID;

BONE DENSITY; BONE METABOLISM; CROHN DISEASE; DISEASE COURSE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEADACHE; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSOMNIA; LETTER; LONG TERM CARE; MENSTRUAL CYCLE; OSTEOPENIA; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; RISK ASSESSMENT; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CROHN DISEASE; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; REMISSION INDUCTION; SAFETY; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548635354     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20145     Document Type: Letter

References (8)

1. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699-706.
2. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117: 49-57.
3. Greenberg RG, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331:836-841.
4. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339:370-374.
5. Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Camperi M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomised, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100:1780-1787.
6. Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn's disease - results of a 12 month study. Global budesonide study group. Aliment Pharmacol Ther. 1998;12:175-183.
7. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:363-371.
8. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3:113-121.